Abbott’s Depakote Off-Label Settlement With DoJ Includes Court Probation
This article was originally published in The Pink Sheet Daily
In a new twist, Abbott’s CEO and board must certify company’s compliance program with the court’s probation office. The requirements of the $1.5 billion settlement will transfer to Abbvie, the pharma company spinning out of Abbott.
You may also be interested in...
$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.
Seventh Circuit reinstates employer benefit funds’ complaint over off-label promotion of Depakote, allowing them to make case they were not properly compensated; courts have issued disparate opinions in such cases.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.